Accepted for Publication: June 2, 2014.
Published Online: September 1, 2014. doi:10.1001/jamaneurol.2014.1895.
Study concept and design: Cohen, Krishnan, Goodman, Wang, Polman, Rudick.
Acquisition, analysis, or interpretation of data: Potts, Wang, Havrdova, Rudick.
Drafting of the manuscript: Cohen, Krishnan, Wang, Polman, Rudick.
Critical revision of the manuscript for important intellectual content: Cohen, Krishnan, Goodman, Potts, Wang, Havrdova, Rudick.
Statistical analysis: Potts, Wang.
Obtained funding: Polman.
Administrative, technical, or material support: Havrdova.
Study supervision: Rudick.
Conflict of Interest Disclosures: Dr Cohen has received personal compensation as a consultant from EMD Serono, Innate Immunotherapeutics, Genzyme, and Novartis and research support paid to his institution from Biogen Idec, Genzyme, Novartis, Receptos, Synthon, Teva, and Vaccinex. Dr Krishnan serves on the Biogen Idec Fampridine International Advisory Board and has received consulting fees from Biogen Idec and speaker fees from Bayer HealthCare, Biogen Idec, CSL Biotherapies, and Pfizer. Dr Goodman has received personal compensation for consulting services from Acorda Therapeutics, Alexion, Avanir, Biogen Idec, EMD Serono, Genzyme, Grifols, GW Pharma, Medison, Mylan, Novartis, Otsuka, Pfizer, Sanofi, Teva, and Vaccinex and financial support for research activities from Acorda Therapeutics, Biogen Idec, EMD Serono, Genzyme, Novartis, Ono, Roche, Sanofi, Sun Pharma, Takeda, and Teva. Dr Havrdova has been supported by contracts MSM 0021620849 and PRVOUK-P26/LF1/4 from the Czech Ministry of Education and has received personal compensation for consulting services and clinical trials from Biogen Idec, Merck, Novartis, Sanofi, and Teva. Dr Polman has received honoraria, consultation fees, or research support from Actelion, Bayer HealthCare, Biogen Idec, GlaxoSmithKline, Merck Serono, MorphoSys AG, Novartis, Roche, Teva, and UCB. The University of New South Wales has received research funding from Biogen Idec. No other disclosures were reported.
Funding/Support: This study was supported by Biogen Idec, including funding for editorial support in the development of this article.
Role of the Sponsor: The study sponsor designed the original clinical studies in collaboration with scientific advisory committees (Dr Cohen was the lead academic advisor for the IMPACT study; Dr Polman, for the AFFIRM study; and Dr Rudick, for the SENTINEL study). The study sponsor also participated with the authors of those studies in the collection and management of data. The study sponsor participated with the authors in the design of the current post hoc analyses, contributed to the analysis and interpretation of data, provided assistance in manuscript preparation, and reviewed and provided feedback on the manuscript to the authors.
Additional Contributions: The late Christian Confavreux, Service de Neurologie A and Fondation Eugène Devic EDMUS, Hospices Civils de Lyon, Lyon, France, contributed to the development of this study. Biogen Idec provided funding for editorial support in the development of this report; Alison Gagnon, PhD, Excel Scientific Solutions, wrote the first draft of the manuscript based on input from authors, and Elizabeth Wassmer, MLS, Excel Scientific Solutions, copyedited and styled the manuscript per journal requirements.